Radiotherapy combined with anti-angiogenic and immunotherapy is an effective option for advanced unresectable iCCA. It also emphasizes that active pathological biopsy is essential for new hepatic lesions after iCCA remission to clarify diagnosis and avoid misdiagnosis-induced inappropriate treatment.

12 days ago

Journal

AFP (Alpha-fetoprotein)

AiRuiKa (camrelizumab) • AiTan (rivoceranib)

12d

Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy. (PubMed, Breast)

TFLR is a frequent, reversible MRI finding in TNBC treated with camrelizumab-based neoadjuvant immuno-chemotherapy. Largest nodule diameter ≥9 mm is a strong, independent predictor of pathological complete response and represents a promising early, non-invasive imaging biomarker of immunotherapeutic efficacy.

12 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

AiRuiKa (camrelizumab)

12d

Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. (PubMed, NPJ Precis Oncol)

This inhibitory effect was mediated through the regulation of Exo70. Collectively, our findings indicate that apatinib enhances the efficacy of camrelizumab in pMMR/MSS colorectal cancer and provide a theoretical rationale for the combined use of camrelizumab and apatinib in this patient population.

12 days ago

Journal • pMMR

PD-L1 (Programmed death ligand 1)

AiRuiKa (camrelizumab) • AiTan (rivoceranib)

13d

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)

P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027

13 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)

Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)

14d

Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping. (PubMed, Discov Oncol)

While vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.

14 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)

PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR amplification • MET exon 14 mutation • MET mutation

Xalkori (crizotinib) • AiRuiKa (camrelizumab) • Endostar (recombinant human endostatin) • vebreltinib (APL-101)

19d

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma (clinicaltrials.gov)

P2, N=57, Recruiting, Sun Yat-sen University

19 days ago

New P2 trial

AiRuiKa (camrelizumab)

19d

Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial. (PubMed, J Gynecol Oncol)

Enrolled patients will receive 1 cycle of chemotherapy (nab-paclitaxel + cisplatin), 2 cycles of chemotherapy combined with camrelizumab, and 3 cycles of camrelizumab alone. Secondary endpoints include the negative human papillomavirus conversion rate, pregnancy rate, miscarriage rate, live birth rate, preterm birth rate, adverse events, quality of life, event-free survival, and overall survival. ClinicalTrials.gov Identifier: NCT06289062.

19 days ago

P2 data • Journal

PD-L1 (Programmed death ligand 1)

cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel

19d

Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs. (PubMed, J Gastrointest Oncol)

This study aimed to evaluate the prognostic significance of TMB in patients with unresectable HCC undergoing TACE combined with immunotherapy (camrelizumab) and anti-angiogenic drugs...Cox regression indicated high TMB as an independent predictor of improved PFS and OS. TMB was a valuable prognostic biomarker for HCC patients undergoing TACE with immunotherapy and anti-angiogenic agents, correlating with enhanced survival and treatment response.

19 days ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

TMB (Tumor Mutational Burden)

TMB-H • TMB-L

AiRuiKa (camrelizumab)

19d

MA-HCC-II-015: A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma (clinicaltrials.gov)

P2, N=21, Completed, Shandong Cancer Hospital and Institute | Active, not recruiting --> Completed

19 days ago

Trial completion

5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium